Managing Infliximab Reinduction After temporary Discontinuation of Drug

Brief description of study

The purpose of this study is to determine what is the best schedule for restarting infliximab (also known as Remicade) in patients with inflammatory bowel disease (IBD), specifically ulcerative colitis (UC) and Crohn’s disease (CD), who have undergone infliximab infusions before. We will not be involved in determining how you restart infliximab, but will track what happens with your IBD control once the medication is restarted. We will assess your clinical response to restarting treatment by collecting information (surveys, medical chart information) and samples (blood and stool).


Clinical Study Identifier: s15-01180
ClinicalTrials.gov Identifier: NCT02771457
Principal Investigator: Lea Ann Chen
Currently Recruiting

Contact the research team to learn more about this study.


By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.